Machine learning model demonstrates stunting at birth and systemic inflammatory biomarkers as predictors of subsequent infant growth - A four-year prospective study by Harrison, Elizabeth et al.
eCommons@AKU 
Department of Paediatrics and Child Health Division of Woman and Child Health 
10-30-2020 
Machine learning model demonstrates stunting at birth and 
systemic inflammatory biomarkers as predictors of subsequent 
infant growth - A four-year prospective study 
Elizabeth Harrison 
University of Virginia, Charlottesville, VA, USA. 
Sana Syed 
Aga Khan University, sana.syed@aku.edu 
Lubaina Ehsan 
University of Virginia, Charlottesville, VA, USA. 
Najeeha Talat Iqbal 
Aga Khan University, najeeha.iqbal@aku.edu 
Kamran Sadiq 
Aga Khan University, kamran.sadiq@aku.edu 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr 
 Part of the Maternal and Child Health Commons, and the Pediatrics Commons 
Recommended Citation 
Harrison, E., Syed, S., Ehsan, L., Iqbal, N., Sadiq, K., Umrani, F., Ahmed, S., Rahman, N., Jakhro, S., Ma, J. Z., 
Hughes, M., Ali, S. (2020). Machine learning model demonstrates stunting at birth and systemic 
inflammatory biomarkers as predictors of subsequent infant growth - A four-year prospective study. BMC 
Pediatrics, 20(1), 498. 
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/957 
Authors 
Elizabeth Harrison, Sana Syed, Lubaina Ehsan, Najeeha Talat Iqbal, Kamran Sadiq, Fayyaz Umrani, Sheraz 
Ahmed, Najeeb Rahman, Sadaf Jakhro, Jennie Z. Ma, Molly Hughes, and Syed Asad Ali 
This article is available at eCommons@AKU: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr/957 
RESEARCH ARTICLE Open Access
Machine learning model demonstrates
stunting at birth and systemic
inflammatory biomarkers as predictors of
subsequent infant growth – a four-year
prospective study
Elizabeth Harrison1,2†, Sana Syed1,3*†, Lubaina Ehsan1, Najeeha T. Iqbal3, Kamran Sadiq3, Fayyaz Umrani3,
Sheraz Ahmed3, Najeeb Rahman3, Sadaf Jakhro3, Jennie Z. Ma4, Molly Hughes5 and S. Asad Ali3*
Abstract
Background: Stunting affects up to one-third of the children in low-to-middle income countries (LMICs) and has
been correlated with decline in cognitive capacity and vaccine immunogenicity. Early identification of infants at risk
is critical for early intervention and prevention of morbidity. The aim of this study was to investigate patterns of
growth in infants up through 48 months of age to assess whether the growth of infants with stunting eventually
improved as well as the potential predictors of growth.
Methods: Height-for-age z-scores (HAZ) of children from Matiari (rural site, Pakistan) at birth, 18 months, and 48
months were obtained. Results of serum-based biomarkers collected at 6 and 9months were recorded. A
descriptive analysis of the population was followed by assessment of growth predictors via traditional machine
learning random forest models.
Results: Of the 107 children who were followed up till 48 months of age, 51% were stunted (HAZ < − 2) at birth
which increased to 54% by 48 months of age. Stunting status for the majority of children at 48 months was found
to be the same as at 18 months. Most children with large gains started off stunted or severely stunted, while all of
those with notably large losses were not stunted at birth. Random forest models identified HAZ at birth as the
most important feature in predicting HAZ at 18 months. Of the biomarkers, AGP (Alpha- 1-acid Glycoprotein), CRP
(C-Reactive Protein), and IL1 (interleukin-1) were identified as strong subsequent growth predictors across both the
classification and regressor models.
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Conclusion: We demonstrated that children most children with stunting at birth remained stunted at 48 months of
age. Value was added for predicting growth outcomes with the use of traditional machine learning random forest
models. HAZ at birth was found to be a strong predictor of subsequent growth in infants up through 48 months of
age. Biomarkers of systemic inflammation, AGP, CRP, IL1, were also strong predictors of growth outcomes. These
findings provide support for continued focus on interventions prenatally, at birth, and early infancy in children at
risk for stunting who live in resource-constrained regions of the world.
Keywords: Infant growth, Systemic inflammatory biomarkers, Growth predictors
Background
Stunting affects up to one-third of the children in low-to-
middle income countries (LMICs) [1]. It is indicative of a
failure to achieve genetic potential for height (more than
two standard deviations [SD] below the World Health
Organization international standards for growth) [2, 3].
Long-term devastating consequences of stunting have
been reported which include permanent cognitive impair-
ments, oral vaccine response failure, and diminished im-
munocompetence [1, 4]. It further accounts for 1.2 million
deaths per year among children under 5 years of age [1].
Global income has been estimated to increase by $176.8
billion per year if linear growth failure is eliminated [5].
Linear growth improvement has been reported by previ-
ous studies to be refractory to nutritional interventions [6,
7]. This prompts the need to explore whether growth
eventually improves (e.g. at 48months of age) and individ-
uals who are at risk. This will enable eradication of the
factors leading to stunting and also warrants well-
designed trials to elucidate any and all food-based inter-
ventions that might have growth-promoting potential [6].
The age of stunting has direct implications for the pro-
gression of growth, as well as the timing and nature of ap-
propriate interventions. Intrauterine growth restriction
and small size at birth are strongly associated with risk of
stunting at 24months of age [8]. Most relevant studies
have shown that major linear growth failure occurs in the
first 48months of life and beyond this age catch-up
growth is rare due to a lack of change in nutrition or en-
vironment for older children [9, 10]. A large body of evi-
dence suggests that the first 1000 days from conception is
a critical window in which interventions to address mal-
nutrition will be most effective; however, little is known
about the impact on linear growth of nutritional interven-
tions in children greater than 2 years of age [6].
The early identification of at-risk infants is critical for
early intervention and prevention of subsequent morbid-
ity. Previous studies have shown increased concentrations
of inflammatory biomarkers and decreased concentrations
of anabolic growth factors such as insulin-like growth
factor-1 (IGF-1) to be associated with stunting [4]. Such
studies often utilize parametric methods in their data ana-
lyses even though nonparametric machine learning-based
approaches, such as random forests, frequently outper-
form parametric approaches in studies with a larger num-
ber of variables than observations [11]. Further, with the
need for reliable methods to characterize different growth
patterns [12], random forest models are robust to overfit-
ting specially if hyperparameters are tuned which in-
creases their applicability in terms of being able to fit
more than just a particular set of data [13]. These random
forest models are often using for biomedical research
which involves multiple variables such as biomarkers that
can predict ovarian cancers [14], neuroimaging and bio-
logical data for patients with Alzheimer’s disease [15],
genes identified via microarray for various diseases [16],
among others. This led to the use of random forest
model-based approach for predicting subsequent infant
growth in our study. It has also been reported that growth
characterization models using z-scores were superior in
terms of accurate fits compared to fitting model to the ori-
ginal scale for length or height measurement [12] due to
which we utilized Height for Age z-scores (HAZ) for our
model.
The aim of our study was to investigate patterns of
growth in infants up through 48months of age to assess
whether there were improvements, as well as potential
predictors of growth such as systemic biomarkers and
anthropometric measurements taken at birth.
Methods
Data collection
Initially data was collected part of a 4-year prospective
parent study for children up till 24 months of age where
researchers at Aga Khan University in Pakistan collected
data for 380 children from the rural village of Matiari,
Sindh, Pakistan [17]. For the purpose of this sub-study,
researchers revisited the patients in order to obtain add-
itional consent for anthropometric measurements to be
obtained at 48 months of age as the primary end-point.
Based on this, the variables utilized for this manuscript
were anthropometric measurements collected from birth
through the twenty fourth month of life (as part of par-
ent study) and then additionally collected at 48 months
of age (based on additional consent acquired for this
sub-study) along with the associated demographic and
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serologic laboratory test data. All anthropometric mea-
surements were converted into z-scores using the World
Health Organization child growth standards. Children
who did not meet growth and nutritional requirements
were subject to additional investigations and interven-
tions as part of the parent study.
Ethics approval
This study was approved by the Ethical Review Commit-
tee of Aga Khan University in Karachi, Pakistan; written
informed consent was obtained from parents and/ or
guardians.
Analysis overview
Our analysis was focused on: (1) descriptive study popu-
lation characterization; and, (2) identification of subse-
quent growth predictors via random forest analysis using
the anthropometric measurements and biomarker levels
collected in the first year of life. Visualizations used to
aid descriptive analysis included scatter plots and spa-
ghetti plots. Random forests analysis identified predic-
tors of growth via classification and regression. With the
aid of additional visualizations, these results were also
used to rank the predictors of linear growth at 20
months of life. The predictability of the top 35 variables
was then estimated using a linear model. Data prepar-
ation, modeling, and analysis were all completed using
the Python coding language in Jupyter Notebook, an
open-source development environment. The detailed
methods for descriptive and random forest analysis are
provided below.
Descriptive analysis
Data exploration initially focused on 48month out-
comes. Of the original cohort (n = 380), which was
followed for 24 months, 112 infants from the same co-
hort participated in the follow-up study up till 48
months of age. Out of the 112, 107 infants had sufficient
anthropometric data to be included in analysis. Stunting
and growth failure in this study were evaluated using
HAZ. Stunting was defined as HAZ two standard devia-
tions (SD) below the mean (HAZ < − 2).
Mean HAZ was calculated across the follow-up popu-
lation at three time points: (1) at enrollment (< 1 month
of age); (2) at 18 months of age; and, (3) at 48 months of
age. Patterns in the distribution of stunting across both
sexes were examined at each point. Then the influence
of location was examined including any patterns associ-
ated within the village or Union Council. Subsequently,
based on the same three time points for mean HAZ cal-
culation, the population was divided into subgroups
based on stunting (HAZ < − 2) status at each of the study
visits. This allowed for the examination of general
growth trends using categorical variables of stunted
versus not-stunted. Growth trends were also evaluated
using linear regression plots and correlation coefficients
(r; using Pearson correlation), with x and y values based
on the raw HAZ of the individual children at each of the
three time points.
In order to assess the change in growth, this study fur-
ther examined growth trends based on the changes in
HAZ over time (delta HAZ). Delta HAZ were calculated
by subtracting the z-scores at 18 and 48months from
those given at the first clinic visit. With a slightly smaller
subset of 101 children, a spaghetti plot was used to iden-
tify growth patterns in the follow-up cohort using
monthly HAZ measurements from the first 18 months
of life, as well as from the 48-month follow-up visit.
Relevant delta HAZ outliers were then highlighted using
different colors based on whether their delta HAZ was
notably positive or negative which also led to spaghetti
plot-based visualization of the growth trends of the chil-
dren over time.
Random Forest models
This study’s final models were designed to be interpretable,
with a significantly reduced set of predictors (details in
Supplementary Methods as part of Additional File 1). All
models were created using sklearn’s Random Forest Classi-
fication and Regressor packages. These python packages
utilized for random forest analyses have been developed by
Scikit-learn and are state-of-the-art implementation pack-
ages created to maintain an easy-to-use interface tightly in-
tegrated with the Python language [18]. List of biomarkers
and cytokines included for the random forest analyses is
provided in Additional File 2.
Identification of variables that were highly predictive
of stunting was approached in two ways: (1) with a ran-
dom forest classification model using stunted versus
not-stunted as outcomes; and, (2) random forest regres-
sion using HAZ at 18 months as the outcome variable.
For both approaches, an 80–20 test-train split was used.
To minimize bias, children who participated in the
follow-up were divided randomly across training and
testing groups. All numeric variables were scaled using
sklearn’s min_max_scaler.fit_transform() function.
In classification, random forest hyperparameters were
optimized using a grid search. This grid search included
“n” estimators ranging from 5 to 300, max features ran-
ging from 25 to 106 (all features), max depths ranging
from 5 to “None,” minimum sample splits of 2 and 4,
and minimum sample leaves of 1 and 2. The grid search
comprised 300 iterations with 5-fold cross validation.
Optimized parameters included max depth at 100, max
features at 106 (all features), “n” estimators at 80, mini-
mum sample leaf number at 2, and minimum sample
split at 4. All other hyperparameters were set to the
function’s default. Feature importance results were then
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extracted, and the top 35 features of the forest were
plotted using a labeled bar chart with lines over each bar
representing the inter-tree variability of each feature (ex-
plained in non-technical terms as part of Supplementary
Methods; Additional File 1).
In regression, performance of a baseline model using
all default hyperparameters was compared to that of a
model using hyperparameters optimized with a similar
grid search to that noted above. Performance was rela-
tively comparable and highly dependent on random
state, so the baseline random forest regressor model was
used for feature analysis. Again, the top 35 features of
importance were extracted and plotted. These were then
compared to the outputs of the classification model.
Results
Descriptive analysis
A total of 112 children who were followed up to 48
months and 107 out of those with sufficient anthropo-
metric data were included from the follow-up cohort
during initial descriptive analysis (Tables 1 and 2). 46%
were males and 51% were stunted at birth (51% male
among those stunted at birth). At 18 months of age, the
percentage of children with stunting increased to 64%
while the male percentage of this subgroup decreased to
46%. By the 48-month visit, the percentage of stunted
children had dropped back down to 54% with only 40%
of these being male. Using scatter plots and linear fit re-
gression lines, HAZ at birth, 18 months, and 48months
were compared (Fig. 1). While HAZ at birth were weakly
linearly correlated with HAZ at either 18 months or 48
months (r = 0.376; p = 0.0001 and r = 0.162; p = 0.0954,
respectively). HAZ at 18 months showed a stronger posi-
tive linear correlation with HAZ at 48 months (r = 0.604;
p < 0.0001).
The 107 children were examined by dividing them into
groups based on their stunting status at the same time
points (birth, 18 months, and 48 months). As shown in
Table 3, of the 107 children, 20 children consistently
had HAZ above − 2 regardless of age while 30 children
who began stunted (HAZ < − 2) remained stunted at
their 18 and 48 follow ups. Of the 55 children who were
stunted at birth, 12 were not stunted by 18months (and
remained in the normal HAZ range) and an additional
11 were not stunted by 48months of age. Of the 52 chil-
dren who were not stunted at birth, 21 fell into the
stunted range by 18 months and remained stunted at
their 48 month follow-up and an additional 5 children
fell into the stunted range between their 18-month and
48-month checks.
Using a more granular approach in order to better
visualize growth trends spaghetti plots were generated
(Fig. 2). Spaghetti plots included 101 out of the 107 chil-
dren as the excluded six children had less frequent visits
in the first 2 years of the study. As shown in the plot,
there were 9 children with delta HAZ above 2 (z-scores
increased by at least 2 points) and 8 children with delta
HAZ under − 2 (z-scores decreased by at least 2 points).
All those with a positive change in z-score of 2 or more
were noted to be stunted at their first study visit. Con-
versely, all those with a loss in their HAZ of 2 or more
were notably not stunted at their first study visit. Not-
ably, most of the children who dropped in their HAZ ex-
perienced most losses in the first 2 years while children
who grew well (HAZ normal range) experienced highest
gains between the 18 and 48 month visit. Across the en-
tire follow-up cohort, most children appear to gain little
between the 18-month and 48-month visits, though gen-
erally remaining around the same z-score.
Random Forest models
After random forest model implementation and hyper-
parameter optimization, relative feature importance was
extracted and plotted for the top 35 features (Fig. 3). As
shown, the only feature identified with high importance
and an inter-tree variability line which did not cross zero
was the raw HAZ calculated using anthropometry done
at birth. Other relatively important features in this forest
included Alpha- 1-acid Glycoprotein (AGP) and C-
Reactive Protein (CRP) biomarker levels at 9 months, as
well as interleukin-1 (IL1); however, all of these demon-
strated significant variability with some trees assigning
these features low to zero importance. With
optimization, this random forest model predicted stunt-
ing at 18 months of age in the set-aside testing set with
78% accuracy.
Table 1 Patient and Maternal Characteristics of the 107 infants
followed till 48 months of age
Characteristics Frequency (%)
Gender, Male (%) 46
Preterm Birth (%) 52a
Advanced Maternal Age (%) 64a
Breastfed soon after birth (%) 98a
Literate Mother (%) 13a
a – values missing for 6 children
Table 2 Anthropometric measurement based WHZ, HAZ and
WAZ of the 107 infants followed till 48 months of age
Anthropometric
Measurements






WHZ −0.25, ± 1.30 −0.81, ± 0.92 − 0.66, ± 0.89
HAZ −2.09, ± 1.35 −2.37, ± 0.87 − 2.11, ± 0.87
WAZ −1.68, ± 1.17 −1.73, ± 0.91 − 1.73, ± 0.83
Key: WHZ Weight for Height z-score; HAZ Height for Age z-score; WAZ Weight
for Age z-score; SD Standard Deviation
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Using a similar approach using the random forest re-
gressor package, 35 features were once again identified
and plotted (Fig. 4). Although there were a few features
other than HAZ in this model with variability lines that
did not cross zero, these results were inconsistent across
different runs during model development which were
due to changes in the random state assigned to each re-
gressor. Although it is notable that the levels of AGP at
9 months of age presented as a strong feature in the re-
sults of the classification and regression model along
with having reduced variability between the trees of the
regressor random forest model. IL1 and CRP at 6
months was also identified as an important feature
(compared to IL1 and CRP at 9 months with random
forest classification only model).
A baseline random forest regression model using all
default hyperparameters and a model using hyper-
parameters identified with a grid search performed
comparably on an unseen testing set. Both models
predicted HAZ at 18 months with a mean squared
error between 0.7 and 0.8, depending on random
state assignments.
Conspicuously, none of the models identified sex, ges-
tational age, or any of the maternal factors as highly im-
portant features. The only one of these features to be
included in the top 35 of either model was maternal lit-
eracy (in the random forest classifier model) but it was
of minimal importance across all trees in the forest.
Discussion
We investigated the serum biomarker and anthropomet-
ric predictors of the growth of infants up till 48 months
of age among a population from a rural village at an
LMIC. A descriptive analysis was followed by the
utilization of machine learning-based nonparametric
traditional machine learning random forest models
which added value to use of such models for answering
clinical questions such as predictors of growth. The
major results of this work include the following: (1) 51%
of the infants were found to be stunted at birth with
most of them staying stunted at 48 months of age; (2) a
stronger correlation exists between HAZ at 18 and 48
months when compared to the correlation between
HAZ at birth and either 18 or 48months; and, (3) of all
the systemic biomarkers and anthropometric measure-
ments, HAZ at birth, AGP, CRP, and IL1 were found to
be the strongest predictors of stunting.
Most studies have shown that major linear growth fail-
ure occurs in the first 48 months of life; beyond this age,
catch-up growth is rare [9, 10]. A large body of evidence
suggests that the first 1000 days from conception is a
critical window in which interventions to address malnu-
trition will be most effective but little is known about
the impact on linear growth of nutritional interventions
in toddlers over the age of 2 years [6]. In our study,
HAZ at 18 months had a positive linear correlation with
HAZ at 48 months, while HAZ at birth was less strongly
correlated with HAZ at either 18 or 48 month of age.
The positive correlation of HAZ at 18 and 48 months of
age is supported by earlier reporting of minimal levels of
Fig. 1 Comparison of Height for Age z-scores at birth, 18 months, and 48months. Key: HAZ - Height for Age z-score
Table 3 Groups based on stunting status and follow up time
points of the 107 infants followed till 48 months of age






(total n = 107)
Not Stunted Not Stunted Not Stunted 20
Stunted 5
Stunted Not Stunted 6
Stunted 21
Stunted Not Stunted Not Stunted 12
Stunted 2
Stunted Not Stunted 11
Stunted 30
Key: SD Standard Deviation
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catch-up growth from age 2 to 5 years [9]. An increase
in HAZ of children with stunting may also be a result of
regression to the mean as shown in previous studies [10].
HAZ at birth was shown to be a significantly strong
predictor of growth followed by CRP, AGP, and IL1.
Much emphasis has been placed on stunting status at
birth and overall prenatal helth affecting clinical out-
comes in previously published studies including stunting
later on in life and poor neurodevelopmental outcomes
[19–21]. Such findings highlight the importance of inter-
ventions in the early months of life to prevent subse-
quent stunting and its consequences [20]. It is important
to note that nutritional interventions have shown little
to no effect with regard to addressing neurodevelopmen-
tal outcomes and other long-term consequences if the
child’s stunting status is not also addressed [6]. In order
to design and construct trials that truly alleviate or re-
duce the consequences of stunting, the underlying fac-
tors that contribute to stunting itself need to be
understood.
The serological biomarkers CRP, AGP, and IL1 suc-
ceeded stunting at birth in predicting growth among
children. CRP and AGP are acute phase proteins stimu-
lated by the release of cytokines such as IL1, IL6, and
TNF-α (Tumor necrosis factor-α) [15]. CRP rises and
declines rapidly during an acute phase response, whereas
AGP rises more slowly (more than 24 h after onset of in-
flammation) and remains elevated for longer [22–24].
These findings are similar to a previous study by our
group. In our previous work, we found significant corre-
lations between flagellin- and lipopolysaccharide-specific
Immunoglobulin A (LPS-specific IgA), serum CRP, AGP
and Regenerating Gene 1β (Reg1) at 6 months, and mye-
loperoxidase (MPO) at 9 months. In the previous study,
we found that higher anti-LPS IgA levels predicted
greater declines in HAZ over the subsequent 18 months
of follow-up [25]. In contrast to this prior work, the
current work utilizes a machine-learning model to inves-
tigate biomarkers as predictors of growth among infants.
Mixed association between inflammation and growth
outcomes has also been reported previously. A study
done among Zimbabwean infants (an LMIC setting)
showed that levels of inflammatory biomarkers (CRP
and AGP) measured at 6 weeks, 6 months, 12 months,
and 18months were consistently higher in children with
stunting (HAZ < − 2) versus healthy controls (defined as
HAZ > − 0.5) at 18 months [26]. Further, among appar-
ently healthy Zimbabwean infants with increased inflam-
matory biomarkers, the levels of anabolic hormone IGF-
1 were low. This finding highlighted the significance of
even low-grade inflammation with regard to poor
growth outcomes [26]. All findings provide support for
continued focus on interventions at birth and early in-
fancy in children at risk for stunting who live in
resource-constrained regions of the world.
Knowledge about the biomarkers predictive of stunting
is not only important from the perspective of construct-
ing effective interventional trials but also paves the way
for understanding the underlying pathology of stunting.
The health of pregnant mothers has been shown to ef-
fect the infants at birth [27]. It has been reported that
stunting begins in utero and continues for at least the
first 2 years of postnatal life; the period from conception
to a child’s second birthday (the first 1000 days) has
Fig. 2 Spaghetti plot for growth trends of infants with follow up 48 months of age (6 patients excluded due to insufficient anthropometric data).
Key: HAZ - Height for Age z-score
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therefore been identified as the most critical window of
opportunity for interventions [19]. Higher levels of in-
flammatory markers among infants can be due to on-
going inflammation in the pregnant mothers or
infections contracted during early life in the setting of
poor sanitation and hygiene.
Several strengths of our study merit mention. Since this
is a prospective study, all patients underwent biomarker
collection and anthropometric measurements within a
similar time frame. We followed a cohort of children for
not only up through 24months, but 48months of age to as-
sess growth outcomes and predictors and to answer the im-
portant questions regarding growth patterns between 2 and
5 years of age. The repeated measurements of length and
height allowed our analysis evaluate growth status at birth,
18months, and 48months of age along with systemic bio-
marker levels, allowing us to assess the best predictors of
growth beyond 2 years of age. Finally, we utilized a robust
machine learning model to perform random forest analysis
for the investigation of systemic biomarker and anthropo-
metric growth predictors. Due to the prospective nature of
this study, limitations included missing data points for
Pearson correlations between known characteristics of par-
ticipants who failed to return for follow-up or were missing
biomarker results because of sample limitations. This also
prompted the machine learning model to be designed
Fig. 3 Random Forest Classifier based relative feature importance for the top 35 features predicting subsequent infant growth (hyperparameter
optimization done via a grid search with cross-validation – y-axis shows feature importance scores which do not have a specific unit). Key
(alphabetical): AGP – Alpha- 1-acid Glycoprotein; CRP – C-reactive Protein; GLP2 – Glucagon-like peptide 2; HAZ - Height for Age z-score; HuEotaxin –
Human Eotaxin; HuGCSF – Human Granulocyte-colony stimulating factor; HuIL4 – Human Interleukin-8; HuIL7 – Human Interleukin-7; HuIL8 – Human
Interleukin-8; HuIL9 – Human Interleukin-9; HuILra – Human Interleukin-1 Receptor Antagonist; HuIP10 – Human Interferon gamma-induced protein
10;HuPDGFb – Human Platelet Derived Growth Factor Subunit B; HuRANTES – Human RANTES (CCL5; C-C Motif Chemokine Ligand 5); HuTNFa –
Human Tumor necrosis factor-α; HuVEGF – Human Vascular Endothelial Growth Factor; LPSIgAOD – Lipopolysaccharide IgA Optical Density; LPSIgGOD
– Lipopolysaccharide IgG Optical Density; MotherLiterate – Literacy Status of the Mother; MPO – Myeloperoxidase; NEO – Neopterin; Reg1Serum –
Serum Regenerating Gene 1β. Note: ‘ln’ before a variable refers to natural logarithm, ‘_9mo’ after a variable refers to the biomarker being collected at
9months of follow-up, variables without mention of a time frame were collected at birth
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based on sufficient data available at 18months of age rather
than 48months of age.
An interesting question for future analysis will be the
assessment of in-utero growth and inflammation as po-
tential predictors of subsequent infant growth. Further,
investigation of maternal factors, including systemic in-
flammation, might answer the important unanswered
question regarding their role in the growth of the child
along with stunting and its prevention.
Conclusion
We described the growth of infants up through 48months
of age and investigated the potential indicators of
subsequent growth. While several of our findings such HAZ
at birth, AGP, CRP, and IL1 as predictors of subsequent
growth)reiterate previous data, our work solidifies previous
assessments of growth through 2 years of age and utilizes a
robust a machine learning approach to confirm these mea-
sures as predictive of early infant growth patterns. This is
significant as it stresses the need to investigate maternal fac-
tors leading to stunting. It also highlights specific biomarkers
that need to be factored in during construction of future tri-
als targeted towards improvement of growth. These findings
provide support for continued focus on interventions at
birth and early infancy in children at risk for stunting who
live in resource-constrained regions of the world.
Fig. 4 Random Forest Regressor based relative feature importance for the top 35 features predicting subsequent infant growth (y-axis shows
feature importance scores which do not have a specific unit). Key (alphabetical): AGP – Alpha- 1-acid Glycoprotein; CRP – C-reactive Protein; GLP2
– Glucagon-like peptide 2; HAZ - Height for Age z-score; HuEotaxin – Human Eotaxin; HuGCSF – Human Granulocyte-colony stimulating factor;
HuIL4 – Human Interleukin-8; HuIL7 – Human Interleukin-7; HuIL8 – Human Interleukin-8; HuIL9 – Human Interleukin-9; HuILra – Human
Interleukin-1 Receptor Antagonist; HuIP10 – Human Interferon gamma-induced protein 10;HuPDGFb – Human Platelet Derived Growth Factor
Subunit B; HuRANTES – Human RANTES (CCL5; C-C Motif Chemokine Ligand 5); HuTNFa – Human Tumor necrosis factor-α; HuVEGF – Human
Vascular Endothelial Growth Factor; LPSIgAOD – Lipopolysaccharide IgA Optical Density; LPSIgGOD – Lipopolysaccharide IgG Optical Density;
MotherLiterate – Literacy Status of the Mother; MPO – Myeloperoxidase; NEO – Neopterin; Reg1Serum – Serum Regenerating Gene 1β. Note: ‘ln’
before a variable refers to natural logarithm, ‘_9mo’ after a variable refers to the biomarker being collected at 9 months of follow-up, variables
without mention of a time frame were collected at birth
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